(Press-News.org) A physician who received an experimental Ebola vaccine after experiencing a needle stick while working in an Ebola treatment unit in Sierra Leone did not develop Ebola virus infection, and there was strong Ebola-specific immune responses after the vaccination, although because of its limited use to date, the effectiveness and safety of the vaccine is not certain, according to a study appearing in JAMA.
On September 26, 2014, a 44-year-old physician from the United States caring for patients in an Ebola treatment unit in Sierra Leone experienced an accidental needle stick, which was estimated to pose a significant risk of infection. Given the concern about potentially lethal Ebola virus disease, the patient was offered, and provided his consent for, postexposure vaccination with an experimental vaccine, VSVΔG-ZEBOV (which has entered a clinical trial for the prevention of Ebola in West Africa). Forty-three hours after exposure, the patient boarded a jet for medical evacuation to the United States and received the vaccine intramuscularly.
Mark J. Mulligan, M.D., of Emory University, Atlanta, and colleagues assessed the patient's response to the vaccine. The patient developed malaise, nausea and fever 12 hours after the vaccination while on the transport jet. A physical exam in the U.S. approximately 14 hours postvaccination (performed at the National Institutes of Health Special Clinical Studies Unit) indicated the patient was in mild to moderate distress from fever, nausea, malaise, myalgia (muscle pain), and chills. On day 2, the fever declined; however, severe symptoms continued along with mild nausea and arthralgia (joint pain). On days 3 through 5, the patient experienced resolution of symptoms and laboratory abnormalities. By day 7, he was completely asymptomatic.
Blood tests detected Ebola virus glycoprotein-specific antibodies and strong Ebola-specific adaptive immune responses. "The clinical syndrome and laboratory evidence were consistent with vaccination response and no evidence of Ebola virus infection was detected," the authors write.
"In the current patient, a self-limited, moderate to severe clinical syndrome began at 12 hours postvaccination. Future decision making about using this experimental vaccine for postexposure vaccination will need to balance the risks of harm from the vaccine or possible Ebola infection (both were unknowns at the time of the patient's exposure) against the possible benefit of vaccination (also unknown at the time of the patient's treatment)."
"Neither the safety nor the efficacy of the VSVΔG-ZEBOV vaccine for postexposure protection can be learned from this single case, but the clinical and laboratory parameters are informative at a time when there is a need to garner all information available on Ebola vaccines."
(doi:10.1001/jama.2015.1995; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Emergency Treatment for Exposure to Ebola Virus
Thomas W. Geisbert, Ph.D., of the University of Texas Medical Branch, Galveston, writes in an accompanying editorial that the most effective way to prevent and control outbreaks and to protect high-risk personnel, including medical staff and laboratory workers, is through the use of preventive vaccines along with use of appropriate personal protective equipment.
"Historically, there has been a small global market for developing an Ebola virus vaccine and there was no financial interest for large pharmaceutical companies to become involved. The current epidemic has spurred substantial scientific activity to develop vaccines."
"Although it is not possible to know with absolute certainty whether the first-generation VSVΔG-ZEBOV vaccine used to treat the potential high-risk exposure had any influence on survival of the exposed patient in the report by Lai et al, this incident serves as an example of how important it is to have safe and effective countermeasures available in sufficient quantities that can be rapidly deployed for emergency use for both medical workers and affected populations."
(doi:10.1001/jama.2015. 2057; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: Please see the article for additional information, including financial disclosures, funding and support, etc.
INFORMATION:
A new study by researchers at the Intermountain Medical Center Heart Institute has found that screening for and treating depression could help to reduce the risk of heart disease in patients with moderate to severe depression.
Researchers at the Intermountain Medical Center Heart Institute, the flagship facility for the Intermountain Healthcare system based in Salt Lake City, analyzed the health records and rates of death, coronary artery disease and stroke of more than 26,000 patients treated by Intermountain over a three-year period.
This is the first study to assess ...
A low-cost antiseptic used to cleanse the cord after birth could help reduce infant death rates in developing countries by 12%, a systematic review published in The Cochrane Library suggests. Authors of the review found that when chlorhexidine was used on babies born outside of a hospital, it reduces the number of newborn babies who died or suffer from infections.
A third of deaths in newborn babies are caused by infections. As one of the World Health Organisation's Essential Medicines, chlorhexidine has been used in hospitals and other medical settings to prevent bacterial ...
More young people than ever are getting most of their information about sexual matters from school, but the majority feel they are not getting all the information they need, and men in particular are missing out, according to new research published in BMJ Open.
The findings come from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3), the largest scientific study of sexual health and lifestyles in Britain. The research was carried out by UCL (University College London), the London School of Hygiene & Tropical Medicine, and NatCen Social Research. ...
CHICAGO --- Walking barefoot on sand "felt like walking on glass" for Keith Wenckowski, who has lived with type-one diabetes for more than two decades.
One of the participants in a new Northwestern Medicine study who suffered from painful diabetic neuropathy (PDN), Wenckowski finally found relief from the constant foot pain that required him to wear shoes at all times, even to the beach.
The study found that those with PDN who received two low dose rounds of a non-viral gene therapy called VM202 had significant improvement of their pain that lasted for months.
"I ...
Methane is one hot gas. It's a prominent component of natural gas, an important atmospheric gas, and a product of both biology and chemical reactions. Its presence was recently confirmed in the atmosphere of Mars by NASA's Curiosity Rover and it has made the news both as a critical greenhouse gas and as a groundwater contaminant resulting from fracking. Yet, while methane seems to be everywhere, many questions remain about the reactions that produce and consume this high-energy compound.
"Deciphering the many pathways by which methane is produced is one of the holy grails ...
For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. A team of scientists at the Broad Institute and MIT's David H. Koch Institute for Integrative Cancer Research have pioneered the use of this technology to "knock out," or turn off, all genes across the genome systematically in an animal model of cancer, revealing genes involved in tumor evolution and metastasis and paving the way for similar studies in other cell types and diseases. The work appears online March 5 in Cell.
"Genome-scale ...
A molecule found in some plants can combat weight gain induced by a high-fat diet, but only in female mice, not males. 7,8-dihydroxyflavone (7,8-DHF) is thought to mimic the effects of a growth factor induced by exercise.
Emory researchers led by Keqiang Ye, PhD, have shown that female mice treated with 7,8-DHF could consume a high-fat diet without gaining weight. In the mice, 7,8-DHF could increase energy expenditure by acting on muscle cells, without suppressing appetite.
"An equivalent diet pill in humans would allow people to maintain a healthy weight, despite a ...
Did you know that our body produces its own marijuana-like compound to protect us against anxiety? A study led by Ottawa researchers, published today in Neuron, reveals a new biological pathway that regulates this system and suggests that a drug currently in clinical trials to treat obesity might also provide an attractive way to combat anxiety disorders.
"Anxiety and obesity are growing problems in society," said Dr. Hsiao-Huei Chen, associate professor of medicine at the University of Ottawa and a senior scientist at the Ottawa Hospital Research Institute. "Not only ...
Methane is a potent greenhouse gas, second only to carbon dioxide in its capacity to trap heat in Earth's atmosphere for a long time. The gas can originate from lakes and swamps, natural-gas pipelines, deep-sea vents, and livestock. Understanding the sources of methane, and how the gas is formed, could give scientists a better understanding of its role in warming the planet.
Now a research team led by scientists at MIT and including colleagues from the Woods Hole Oceanographic Institution, the University of Toronto, and elsewhere has developed an instrument that can ...
RIVERSIDE, Calif. - Soybean oil accounts for more than 90 percent of all the seed oil production in the United States. Genetically modified (GM) soybean oil, made from seeds of GM soybean plants, was recently introduced into the food supply on the premise that it is healthier than conventional soybean oil.
But is that premise true?
Just barely, say scientists at the University of California, Riverside and their colleagues at UC Davis. The researchers compared the effects of both oils in experiments performed in the lab on mice. They found that the GM soybean oil is ...
